LipidRisk, LLC is a technology discovery company with its primary focus on advanced lipoprotein testing. Further development of cardiovascular disease treatment, concussion treatment and detection are also a focus. The company goal is to continue the advancement of these technologies through alliances and collaboration with experts in these disciplines.
LipidRisk, LLC was formed in 2016 as consulting and assay development company. Dr. Troup is the inventor of the Lipoprotein Particle Profile (LPP) assay and is uniquely qualified to assist in the understanding and interpretation of lipoprotein test results for the development of new technologies for risk assessment.
The first patent pending assay developed by LipidRisk is the HDL3-P Activation Index. This assay compares fasting and postprandial lipoprotein particle profiles to show the activation of HDL3-P as an indicator of reverse cholesterol transport potential.
Other areas of interest include research on a the "Time of Injury" treatment for concussion and TBI using gallium compounds described in the utility patent by Jan M. Troup issued on 12-8-2015 and a treatment for cardiovascular disease using gallium compounds described in the utility patent by Jan M. Troup issued on 12-17-19.